SPRD/Ztm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) |
Stieber D, et al., Int J Cancer. 2007 Jan 17 |
mammary gland integrity trait |
female |
186 days-191 days |
48 |
11.23 |
null |
0.07 |
0.51 |
necropsy |
0 |
DMBA oral gavage |
0 |
|
necropsy |
|
11340 |
73 |
SS-Chr 13BN/Mcwi |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 |
mammary gland integrity trait |
female |
152 days-162 days |
13 |
5.33 |
null |
1.21 |
4.38 |
necropsy |
0 |
DMBA oral gavage |
105 |
days |
necropsy |
|
11501 |
86 |
WF/NHsd |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) |
Haag JD, et al., Cancer Res 2003 Sep 15;63(18):5808-12 |
mammary gland integrity trait |
female |
155 days-160 days |
30 |
8.1 |
null |
0.7 |
3.83 |
necropsy |
|
|
0 |
|
|
3X3 mm diameter or larger |
11746 |
143 |
WF/NHsd |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) |
Lan H, et al., Genetics 2001 Jan;157(1):331-9 |
mammary gland integrity trait |
female |
169 days-174 days |
21 |
7.3 |
null |
0.98 |
4.5 |
necropsy |
|
|
0 |
|
|
3X3 mm diameter or larger |
11742 |
141 |
WF.WKY-(D5Rat26-D5Uwm42)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) |
Samuelson DJ, et al., Carcinogenesis 2003 Sep;24(9):1455-60 |
mammary gland integrity trait |
female |
155 days-160 days |
29 |
5.7 |
null |
0.6 |
3.23 |
unspecified method |
|
|
0 |
|
|
3X3 mm diameter or larger |
11745 |
142 |
SPRD.WKY-(D18Wox8-D18Rat44)/Ibmm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 133 days) |
Piessevaux G, et al., Mamm Genome. 2008 Dec 4 |
mammary gland integrity trait |
female |
0 days
| 46 |
7.61 |
null |
0.45 |
3.05 |
manual palpation method |
0 |
DMBA oral gavage |
133 |
days |
|
|
11356 |
74 |
WF.WKY-(D5Uwm76-D5Uwm61)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
40 |
4.2 |
null |
0.4 |
2.53 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70297 |
653 |
WF.WKY-(D5Uwm76-D5Uwm92)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
58 |
4.8 |
null |
0.4 |
3.05 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70304 |
653 |
WF.WKY-(D5Uwm85-D5Uwm92)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
51 |
3.9 |
null |
0.3 |
2.14 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70310 |
653 |
WF.WKY-(D5Uwm88-D5Uwm92)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
58 |
6.9 |
null |
0.6 |
4.57 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70308 |
653 |
WF.WKY-(D7Rat51-D7Rat128)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. |
mammary gland integrity trait |
female |
155 days-160 days |
23 |
8.0 |
null |
0.85 |
4.1 |
in vivo visual assessment |
0 |
DMBA oral gavage |
105 |
days |
|
|
66062 |
654 |
WF.WKY-(D7Uwm25-D7Rat128)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. |
mammary gland integrity trait |
female |
155 days-160 days |
43 |
7.2 |
null |
0.46 |
3.0 |
in vivo visual assessment |
0 |
DMBA oral gavage |
105 |
days |
|
|
66063 |
654 |
SPRD/Ztm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 133 days) |
Piessevaux G, et al., Mamm Genome. 2008 Dec 4 |
mammary gland integrity trait |
female |
0 days
| 17 |
10.89 |
null |
0.43 |
1.77 |
manual palpation method |
0 |
DMBA oral gavage |
133 |
days |
|
|
11354 |
74 |
SS-Chr 16BN/Mcwi |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 |
mammary gland integrity trait |
female |
152 days-162 days |
13 |
6.31 |
null |
1.61 |
5.79 |
necropsy |
0 |
DMBA oral gavage |
105 |
days |
necropsy |
|
11504 |
86 |
WF.WKY-(D5Uwm67-D5Uwm98)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
35 |
3.2 |
null |
0.4 |
2.37 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70296 |
653 |
WF.WKY-(D5Uwm78-D5Uwm84)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
41 |
8.1 |
null |
0.6 |
3.84 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70307 |
653 |
WF.WKY-(D5Uwm78-D5Uwm93)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
27 |
5.0 |
null |
0.5 |
2.6 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70306 |
653 |
WF.WKY-(D5Uwm82-D5Uwm91)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
58 |
3.4 |
null |
0.3 |
2.28 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70312 |
653 |
WF.WKY-(D5Uwm77-D5Uwm91)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
12 |
3.8 |
null |
0.8 |
2.77 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70313 |
653 |
Crl:CD(SD) |
mammary tumor number |
maternal milk (for 20 days) and bisphenol A (250 ug/kg) (for 15 days) then 7,12-dimethyltetraphene (30 mg/kg) (for 1 days) |
Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7. |
mammary gland integrity trait |
female |
0 days-365 days |
24 |
5.0 |
null |
0.88 |
4.31 |
manual palpation method |
0.0 |
|
0 |
|
|
|
76266 |
1558 |
SS.BN-(D6Rat149-D6Arb3)/Mcwi |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 |
mammary gland integrity trait |
female |
152 days-162 days |
14 |
4.77 |
null |
0.64 |
2.39 |
necropsy |
0 |
DMBA oral gavage |
105 |
days |
necropsy |
|
65571 |
86 |
WF.COP-(D7Rat39-D7Uwm12)/1Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. |
mammary gland integrity trait |
female |
155 days-160 days |
16 |
2.4 |
null |
0.4 |
1.6 |
in vivo visual assessment |
0 |
DMBA oral gavage |
105 |
days |
|
|
66065 |
654 |
SPRD.WKY-(D5Rat190-D5Rat114)/Ibmm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) |
Stieber D, et al., Int J Cancer. 2007 Jan 17 |
mammary gland integrity trait |
female |
186 days-191 days |
14 |
3.93 |
null |
0.17 |
0.64 |
necropsy |
0 |
DMBA oral gavage |
0 |
|
necropsy |
|
11341 |
73 |
SPRD.WKY-(D5Rat190-D5Rat114)(D18Rat102-D18Rat44)/Ibmm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 133 days) |
Piessevaux G, et al., Mamm Genome. 2008 Dec 4 |
mammary gland integrity trait |
female |
0 days
| 33 |
5.0 |
null |
0.44 |
2.53 |
manual palpation method |
0 |
DMBA oral gavage |
133 |
days |
|
|
11358 |
74 |
WKY/NHsd |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) |
Lan H, et al., Genetics 2001 Jan;157(1):331-9 |
mammary gland integrity trait |
female |
169 days-174 days |
17 |
0.0 |
null |
|
|
necropsy |
|
|
0 |
|
|
3X3 mm diameter or larger |
11741 |
141 |
WF.WKY-(D5Uwm78-D5Uwm98)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
32 |
2.8 |
null |
0.3 |
1.7 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70301 |
653 |
WF.WKY-(D5Uwm76-D5Got18)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
27 |
3.5 |
null |
0.4 |
2.08 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70300 |
653 |
WF.WKY-(D5Uwm67-D5Uwm81)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
26 |
8.3 |
null |
0.7 |
3.57 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70303 |
653 |
WF.WKY-(D7Rat171-D7Rat128)/1Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. |
mammary gland integrity trait |
female |
155 days-160 days |
17 |
3.5 |
null |
0.61 |
2.5 |
in vivo visual assessment |
0 |
DMBA oral gavage |
105 |
days |
|
|
66060 |
654 |
WF.WKY-(D5Uwm95-D5Uwm98)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
36 |
7.4 |
null |
0.6 |
3.6 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70302 |
653 |
WF.WKY-(D7Rat171-D7Rat128)/2Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. |
mammary gland integrity trait |
female |
155 days-160 days |
32 |
3.9 |
null |
0.46 |
2.6 |
in vivo visual assessment |
0 |
DMBA oral gavage |
105 |
days |
|
|
66061 |
654 |
WF.COP-(D7Rat39-D7Uwm12)/2Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. |
mammary gland integrity trait |
female |
155 days-160 days |
16 |
2.0 |
null |
0.38 |
1.5 |
in vivo visual assessment |
0 |
DMBA oral gavage |
105 |
days |
|
|
66066 |
654 |
SPRD.WKY-(D18Wox8-D18Rat44)/Ibmm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) |
Stieber D, et al., Int J Cancer. 2007 Jan 17 |
mammary gland integrity trait |
female |
186 days-191 days |
46 |
7.61 |
null |
0.07 |
0.45 |
necropsy |
0 |
DMBA oral gavage |
0 |
|
necropsy |
|
11342 |
73 |
WF/NHsd |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) |
Samuelson DJ, et al., Carcinogenesis 2003 Sep;24(9):1455-60 |
mammary gland integrity trait |
female |
155 days-160 days |
50 |
6.9 |
null |
0.4 |
2.83 |
unspecified method |
|
|
0 |
|
|
3X3 mm diameter or larger |
11743 |
142 |
WF |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (between 126 and 140 days) |
Shepel LA, et al., Genetics 1998 May;149(1):289-99 |
mammary gland integrity trait |
female |
181 days-200 days |
53 |
3.62 |
null |
0.27 |
1.95 |
necropsy |
0.0 |
DMBA oral gavage |
126 |
days |
from 126 to 140 days |
|
66100 |
689 |
WF.WKY-(D5Uwm76-D5Uwm98)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
26 |
3.8 |
null |
0.4 |
2.04 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70298 |
653 |
WF.WKY-(D7Rat171-D7Rat45)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. |
mammary gland integrity trait |
female |
155 days-160 days |
28 |
3.4 |
null |
0.4 |
2.1 |
in vivo visual assessment |
0 |
DMBA oral gavage |
105 |
days |
|
|
66064 |
654 |
SPRD.WKY-(D10Rat91-D10Rat135)/Ibmm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 133 days) |
Piessevaux G, et al., Mamm Genome. 2008 Dec 4 |
mammary gland integrity trait |
female |
0 days
| 25 |
9.24 |
null |
0.65 |
3.25 |
manual palpation method |
0 |
DMBA oral gavage |
133 |
days |
|
|
11357 |
74 |
WF/NHsd |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) |
Haag JD, et al., Cancer Res 2003 Sep 15;63(18):5808-12 |
mammary gland integrity trait |
female |
155 days-160 days |
29 |
6.3 |
null |
0.5 |
2.69 |
necropsy |
0.0 |
|
0 |
|
|
3X3 mm diameter or larger |
70167 |
143 |
Crl:CD(SD) |
mammary tumor number |
maternal milk (for 20 days) and vehicle control condition (for 15 days) then 7,12-dimethyltetraphene (30 mg/kg) (for 1 days) |
Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7. |
mammary gland integrity trait |
female |
0 days-365 days |
32 |
2.84 |
null |
0.31 |
1.75 |
manual palpation method |
0.0 |
|
0 |
|
|
|
76264 |
1558 |
SS/JrHsdMcwi |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 |
mammary gland integrity trait |
female |
152 days-162 days |
40 |
2.45 |
null |
0.21 |
1.32 |
necropsy |
0 |
DMBA oral gavage |
105 |
days |
necropsy |
|
11488 |
86 |
WF.WKY-(D5Wox7-D5Uwm37)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) |
Samuelson DJ, et al., Carcinogenesis 2003 Sep;24(9):1455-60 |
mammary gland integrity trait |
female |
155 days-160 days |
13 |
1.1 |
null |
0.3 |
1.08 |
unspecified method |
|
|
0 |
|
|
3X3 mm diameter or larger |
11744 |
142 |
COP/OlaHsd |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) |
Haag JD, et al., Cancer Res 2003 Sep 15;63(18):5808-12 |
mammary gland integrity trait |
female |
155 days-160 days |
16 |
0.25 |
null |
0.1 |
0.4 |
necropsy |
|
|
0 |
|
|
3X3 mm diameter or larger |
11747 |
143 |
SPRD.WKY-(D5Rat190-D5Rat114)/Ibmm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 133 days) |
Piessevaux G, et al., Mamm Genome. 2008 Dec 4 |
mammary gland integrity trait |
female |
0 days
| 14 |
3.93 |
null |
0.64 |
2.39 |
manual palpation method |
0 |
DMBA oral gavage |
133 |
days |
|
|
11355 |
74 |
WF.WKY-(D5Uwm87-D5Uwm92)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
56 |
6.3 |
null |
0.4 |
2.99 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70309 |
653 |
WF.COP-(D2Mit29-D2Rat201)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) |
Haag JD, et al., Cancer Res 2003 Sep 15;63(18):5808-12 |
mammary gland integrity trait |
female |
155 days-160 days |
19 |
1.5 |
null |
0.3 |
1.31 |
necropsy |
0.0 |
|
0 |
|
|
3X3 mm diameter or larger |
70168 |
143 |
Crl:CD(SD) |
mammary tumor number |
maternal milk (for 20 days) and bisphenol A (25 ug/kg) (for 15 days) then 7,12-dimethyltetraphene (30 mg/kg) (for 1 days) |
Jenkins S, et al., Environ Health Perspect. 2009 Jun;117(6):910-5. doi: 10.1289/ehp.11751. Epub 2009 Jan 7. |
mammary gland integrity trait |
female |
0 days-365 days |
34 |
3.82 |
null |
0.43 |
2.51 |
manual palpation method |
0.0 |
|
0 |
|
|
|
76265 |
1558 |
WF |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18. |
mammary gland integrity trait |
female |
155 days-160 days |
19 |
7.3 |
null |
0.83 |
3.6 |
in vivo visual assessment |
0 |
DMBA oral gavage |
105 |
days |
|
|
66067 |
654 |
SS.BN-(D13Hmgc64-RN34_13048990782)/Mcwi |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 |
mammary gland integrity trait |
female |
152 days-162 days |
14 |
4.86 |
null |
0.7 |
2.63 |
necropsy |
0 |
DMBA oral gavage |
105 |
days |
necropsy |
|
65573 |
86 |
SS-Chr 19BN/Mcwi |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45 |
mammary gland integrity trait |
female |
152 days-162 days |
14 |
8.79 |
null |
1.25 |
4.68 |
necropsy |
0 |
DMBA oral gavage |
105 |
days |
necropsy |
|
11507 |
86 |
WF.WKY-(D5Uwm67-D5Uwm78)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
32 |
8.6 |
null |
0.8 |
4.53 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70299 |
653 |
WF.WKY-(D5Uwm82-D5Uwm92)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
18 |
2.6 |
null |
0.6 |
2.55 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70311 |
653 |
WF.WKY-(D5Uwm78-D5Uwm84)/Uwm |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
29 |
8.8 |
null |
0.7 |
3.77 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70305 |
653 |
WF/NHsd |
mammary tumor number |
7,12-dimethyltetraphene (65 mg/kg) (for 105 days) |
Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106. |
mammary gland integrity trait |
female |
155 days-160 days |
46 |
7.9 |
null |
0.5 |
3.39 |
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
70314 |
653 |